Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | CCR1 | P32246 | 10/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | FASN | P49327 | 2/20 | 0.42 |
| ▸ | MGLL | Q99685 | 3/20 | 0.41 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22729758 | 0.94 | PROKR1 (0.53) | PROKR1FASNMGLL | |
| SCHEMBL22729626 | 0.89 | ALDH1A1 (0.47) | ALDH1A1MAPTHPGDTSHRSMN1; SMN2 | |
| SCHEMBL23116397 | 0.85 | HRH1 (0.42) | PROKR1ALDH1A1MAPTHPGDTSHR | |
| SCHEMBL22729772 | 0.83 | ALDH1A1 (0.42) | ALDH1A1MAPTHPGDTSHRSMN1; SMN2 | |
| SCHEMBL29839360 | 0.83 | ALDH1A1 (0.42) | ALDH1A1MAPTHPGDTSHRSMN1; SMN2 | |
| SCHEMBL22729510 | 0.83 | CCNC (0.42) | PROKR1ALDH1A1MAPTHPGDTSHR | |
| SCHEMBL22729425 | 0.83 | TP53 (0.47) | ALDH1A1MAPTHPGDTSHRSMN1; SMN2 | |
| SCHEMBL22729771 | 0.79 | HTT (0.44) | ALDH1A1MAPTHPGDTSHRSMN1; SMN2 | |
| SCHEMBL22755306 | 0.79 | PROKR1 (0.52) | PROKR1FASNMGLLAVPR1A | |
| SCHEMBL22729839 | 0.79 | ALDH1A1 (0.43) | ALDH1A1MAPTHPGDTSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459325-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-04 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| EP-3747885-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | PROKR1 3517/4885ALDH1A1 2626/4885MAPT 356/4885 |
| US-11459325-B2 | Heterocyclic compound | GBA1, GBA2, GALC | PROKR1 3556/4885ALDH1A1 2660/4885MAPT 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.